Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Quarterly Earnings Results, Hits Expectations

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) released its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01, Briefing.com reports. The company had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The company’s revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.08) EPS.

Aurinia Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ AUPH traded down $0.11 during midday trading on Friday, reaching $5.50. 2,032,563 shares of the stock were exchanged, compared to its average volume of 1,420,359. The company has a market capitalization of $786.61 million, a price-to-earnings ratio of -12.79 and a beta of 1.44. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $11.15. The business has a 50-day simple moving average of $5.52 and a two-hundred day simple moving average of $5.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.60 and a quick ratio of 5.05.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.